Article
CAR T-Cell Therapy in High-Risk Non-Hodgkin Lymphoma
Author(s):
This OncLive® webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma. Join us Tuesday, June 30, 2020 at 7 PM EST.
Date/Time: Tuesday, June 30, 2020 at 7 PM EST
This OncLive® webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma (NHL). Join our leading experts as they discuss important topics and considerations surrounding CAR T-Cell therapy and patients with High-Risk Non-Hodgkin Lymphoma.
Course Topics:
- Rationale for CAR T-Cell therapy in patients with lymphoma
- Review of CAR T-Cell activity in aggressive lymphoma
- Review of CAR T-Cell activity in indolent lymphoma and CLL
- Activity of CAR T-Cell in myeloma
- Review progress on short term and longer term toxicity of CAR T-Cells
- Real-world data compared with results seen on clinical trials
- Navigating referrals in the community
- Future directions for CAR T-Cell therapy in NHL
Chair
Andre H. Goy, MD
Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer - John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology- Hackensack Meridian School of Medicine at Seton Hall University
Professor of Medicine – Georgetown University
Hackensack, NJ
Sponsored by:
